Delving into the Latest Updates on PBL-1427 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

PBL 1427, PBL1427

Target

DPP-4

Action

inhibitors

Mechanism

DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus

Originator Organization

Panacea Biotec Ltd.

Active Organization-

Inactive Organization

Panacea Biotec Ltd.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

PBL 1427 is a Dipeptidyl peptidase (DPP)-IV inhibitor being developed for treatment of type 2 diabetes. Although a number of DPP-IV inhibitors have been described, there still exists a need for new DPP-IV inhibitors that have better half-life, advantageous potency, stability and selectivity, less toxicity and/or better pharmacodynamic properties.

Start Date01 Jul 2012

Sponsor / Collaborator

Panacea Biotec Ltd.

CTRI/2011/12/002220

/ RecruitingPhase 1

A Randomized, Double-Blind, Placebo-Controlled Phase I Study To Determine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers.

Start Date16 Jan 2012

Sponsor / Collaborator

Panacea Biotec Ltd.

[+1]

100 Clinical Results associated with PBL-1427

Login to view more data

100 Translational Medicine associated with PBL-1427

Login to view more data

100 Patents (Medical) associated with PBL-1427

Login to view more data

100 Deals associated with PBL-1427

Login to view more data